ArticleTrials2025
Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06518226 (Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer (TURBO): Phase 2, Randomized Controlled Clinical Trial
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypofractionation in prostate cancer radiotherapy (RT) has drastically reduced fractionation schemes from 35 to 5 fractions for patients with intermediate-risk prostate cancer, providing good oncological outcomes and well-tolerated treatment toxicity. With an ageing population and a subsequently higher volume of patients with localized prostate cancer, optimizing treatment options is essential to maintain a sustainable healthcare system. Magnetic resonance (MR)-guided RT, allows for the delivery of higher doses of radiation with more accuracy, while limiting genitourinary (GU) and gastrointestinal (GI) toxicity. These advantages facilitate the development of ultrahypofractionation schedules in which the number of treatment fractions can be decreased whilst delivering a sufficient dose for oncological control. The objective of the Two-fraction Ultrahypofractionated Radiotherapy with focal BOost (TURBO) trial is to assess if a radiotherapy schedule of 24 Gy to the prostate in two fractions with a boost to the intraprostatic tumor of up to 27 Gy, is safe and tolerable in terms of treatment toxicity, quality of life, and oncological outcomes.
methodsTURBO is a single-center, open-label, randomized controlled trial, designed to assess non-inferiority over standard treatment. Data are collected within the longitudinal Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM). We will include 160 patients with intermediate risk, localized prostate cancer, who are treated on a 1.5 T MR-linear accelerator (MR-Linac) and randomized (1:1). Participants in the control arm (n = 80) will receive standard of care (36.25 Gy in five fractions, delivered in 16-18 days). Participants in the experimental arm (n = 80) are treated with two fractions of 12 Gy to the prostate, with a boost of up to 13.5 Gy to the gross tumor volume (GTV) in 8 days. The main endpoint is Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 GU acute toxicity (up to 90 days after treatment). Secondary outcomes are acute GI toxicity and late GU and GI toxicity 1, 2, and 5 years after treatment, as well as QoL through assessment of patient-reported outcome measures (EORTC-QLQ-C30, EORTC-QLQ-PR15, EQ-5D-5L) and biochemical recurrence and overall survival up to 5 years. DISCUSSION: TURBO compares a 2-fraction radiotherapy course of 12 Gy per fraction to the clinical target volume (CTV) with a simultaneously integrated boost to the GTV of up to 13.5 Gy to a standard 5-fraction course of 7.25 Gy per fraction. The objective is to assess non-inferiority in terms of treatment toxicity and to compare oncological outcomes.
trial registrationClinicalTrials.gov Identifier NCT06518226. Registered on 24 July 2024. First participant included on March 28th 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.